Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel, Stephen A. Harrison, Magdy Elkhashab, et al.
Hepatology (2020) Vol. 72, Iss. 1, pp. 58-71
Closed Access | Times Cited: 269

Showing 1-25 of 269 citing articles:

Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince, Joel T. Haas, Bart Staels
Molecular Metabolism (2020) Vol. 42, pp. 101092-101092
Open Access | Times Cited: 371
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 340
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg, Timon E. Adolph, Michael Dudek, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1596-1607
Closed Access | Times Cited: 305
Molecular physiology of bile acid signaling in health, disease, and aging
Alessia Perino, Hadrien Demagny, Laura A. Velázquez‐Villegas, et al.
Physiological Reviews (2020) Vol. 101, Iss. 2, pp. 683-731
Open Access | Times Cited: 304
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Lulu Sun, Jie Cai, Frank J. Gonzalez
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 335-347
Closed Access | Times Cited: 283
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Claudia Fuchs, Michael Trauner
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 7, pp. 432-450
Closed Access | Times Cited: 254
Targeting fibrosis: mechanisms and clinical trials
Manyu Zhao, Liqun Wang, Mengzhu Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 253
Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 373-392
Closed Access | Times Cited: 234
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Teresa Brevini, Mailis Maes, Gwilym J. Webb, et al.
Nature (2022) Vol. 615, Iss. 7950, pp. 134-142
Open Access | Times Cited: 232
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Jingwei Cai, Bipin Rimal, Changtao Jiang, et al.
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108238-108238
Open Access | Times Cited: 225
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Rohit Loomba, Mazen Noureddin, Kris V. Kowdley, et al.
Hepatology (2020) Vol. 73, Iss. 2, pp. 625-643
Closed Access | Times Cited: 217
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 207
Bile acids and their receptors in metabolic disorders
Stefano Fiorucci, Eleonora Distrutti, Adriana Carino, et al.
Progress in Lipid Research (2021) Vol. 82, pp. 101094-101094
Closed Access | Times Cited: 175
Current treatment of non‐alcoholic fatty liver disease
Rafael Paternostro, Michael Trauner
Journal of Internal Medicine (2022) Vol. 292, Iss. 2, pp. 190-204
Open Access | Times Cited: 174
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman, Tim Rolph
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 166
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
Farnesoid X receptor (FXR): Structures and ligands
Longying Jiang, Huajun Zhang, Desheng Xiao, et al.
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 2148-2159
Open Access | Times Cited: 157
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
Zui Tan, Hongbao Sun, Taixiong Xue, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 155
Bile Acids and FXR: Novel Targets for Liver Diseases
Mary Stofan, Grace L. Guo
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 154
Management of non-alcoholic fatty liver disease
Maria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
BMJ (2021), pp. m4747-m4747
Open Access | Times Cited: 150
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri, Robert Herring, Heidi Kabler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 607-618
Open Access | Times Cited: 146
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 133
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)
Patrizia Burra, Debora Bizzaro, Anna Gonta, et al.
Liver International (2021) Vol. 41, Iss. 8, pp. 1713-1733
Open Access | Times Cited: 117
Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases
Baoyi Guan, Jinlin Tong, Haiping Hao, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 5, pp. 2129-2149
Open Access | Times Cited: 112
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
Arun J. Sanyal, Patricia López, Eric Lawitz, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 392-400
Open Access | Times Cited: 110
Page 1 - Next Page

Scroll to top